Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MLL rearrangement
i
Other names:
HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(10)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (NCT06013423)
Phase 2
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Recruiting
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
06/07/2024
Initiation :
07/06/2024
Primary completion :
10/31/2024
Completion :
10/31/2025
KMT2A • HLA-DRB1 • HLA-B
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (NCT01860937)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
06/05/2024
Initiation :
05/01/2013
Primary completion :
05/01/2025
Completion :
05/01/2025
KMT2A • IKZF1
|
MLL rearrangement • IKZF1 deletion
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene (NCT05886049)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
11/10/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
FLT3 • NPM1 • KMT2A
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation
|
daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06001788)
Phase 1
Kura Oncology, Inc.
Kura Oncology, Inc.
Recruiting
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/30/2024
Initiation :
02/22/2024
Primary completion :
08/01/2026
Completion :
08/01/2027
FLT3 • NPM1 • KMT2A
|
FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • ziftomenib (KO-539) • fludarabine IV
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (AALL1621) (NCT02981628)
Phase 2
Children's Oncology Group
Children's Oncology Group
Recruiting
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
05/30/2024
Initiation :
06/19/2017
Primary completion :
03/31/2026
Completion :
03/31/2026
KMT2A • CD22
|
MLL rearrangement • CD22 expression
|
cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies (NCT02443831)
Phase 1
University College, London
University College, London
Active, not recruiting
Phase 1
University College, London
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
04/01/2016
Primary completion :
12/31/2028
Completion :
12/31/2036
ABL1 • BCR • KMT2A • IGH • CD22 • TCF3
|
KMT2A rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (NCT03114865)
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Cent...
Active, not recruiting
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
05/27/2024
Initiation :
09/05/2017
Primary completion :
06/30/2025
Completion :
06/30/2025
KMT2A
|
MLL rearrangement
|
Blincyto (blinatumomab) • dexamethasone
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
Phase 3
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/24/2024
Initiation :
02/29/2012
Primary completion :
12/31/2022
Completion :
09/22/2024
ABL1 • BCR • RUNX1 • KMT2A • ETV6
|
MLL rearrangement • MLL rearrangement
|
dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/24/2024
Initiation :
11/20/2020
Primary completion :
12/20/2025
Completion :
12/20/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (NCT01995578)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Completed
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/22/2024
Initiation :
12/01/2013
Primary completion :
09/27/2023
Completion :
09/27/2023
FLT3 • KMT2A
|
FLT3 mutation • MLL rearrangement
|
azacitidine
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) (NCT04065399)
Phase 1/2
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Recruiting
Phase 1/2
Syndax Pharmaceuticals
Recruiting
Last update posted :
05/17/2024
Initiation :
11/05/2019
Primary completion :
12/01/2024
Completion :
12/01/2024
KMT2A • NUP98
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement
|
Revuforj (revumenib) • Tybost (cobicistat)
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516)
Phase 1
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Active, not recruiting
Phase 1
Syndax Pharmaceuticals
Active, not recruiting
Last update posted :
05/17/2024
Initiation :
03/09/2022
Primary completion :
05/01/2024
Completion :
06/01/2024
KMT2A • NUP98
|
KMT2A rearrangement • MLL rearrangement
|
cytarabine • cyclophosphamide • Revuforj (revumenib)
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML (KOMET-007) (NCT05735184)
Phase 1
Kura Oncology, Inc.
Kura Oncology, Inc.
Recruiting
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/16/2024
Initiation :
07/18/2023
Primary completion :
05/01/2026
Completion :
05/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
Venclexta (venetoclax) • azacitidine • daunorubicin • ziftomenib (KO-539)
Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
Phase 2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Recruiting
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
05/07/2024
Initiation :
05/01/2023
Primary completion :
10/22/2027
Completion :
10/22/2028
NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • sirolimus • fludarabine IV
Cord Blood Transplant in Adults With Blood Cancers (NCT05884333)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/02/2024
Initiation :
05/22/2023
Primary completion :
05/22/2028
Completion :
05/22/2028
KMT2A
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to (EU PIP Study) (NCT05748171)
Phase 2
Pfizer
Pfizer
Recruiting
Phase 2
Pfizer
Recruiting
Last update posted :
04/30/2024
Initiation :
05/17/2023
Primary completion :
07/11/2028
Completion :
07/09/2031
TP53 • KMT2A • CD22 • TCF3 • PBX1
|
KMT2A rearrangement • MLL rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (APAL2020SC) (NCT04726241)
Phase 1/2
LLS PedAL Initiative, LLC
LLS PedAL Initiative, LLC
Recruiting
Phase 1/2
LLS PedAL Initiative, LLC
Recruiting
Last update posted :
04/22/2024
Initiation :
04/18/2022
Primary completion :
12/31/2026
Completion :
12/31/2026
KMT2A
|
KMT2A rearrangement • MLL rearrangement
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (NCT05761171)
Phase 2
Children's Oncology Group
Children's Oncology Group
Recruiting
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
04/22/2024
Initiation :
01/08/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
KMT2A
|
MLL rearrangement
|
cytarabine • methotrexate • vincristine • Revuforj (revumenib) • Oncaspar liquid (pegaspargase) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
Phase 2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Recruiting
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
04/16/2024
Initiation :
03/30/2018
Primary completion :
01/10/2025
Completion :
11/10/2025
NPM1 • KMT2A • IKZF1 • CEBPA
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411)
Phase 2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Active, not recruiting
Phase 2
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
04/10/2024
Initiation :
01/02/2019
Primary completion :
06/23/2020
Completion :
06/28/2024
FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616)
Phase 1
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Recruiting
Phase 1
OHSU Knight Cancer Institute
Recruiting
Last update posted :
04/09/2024
Initiation :
01/14/2021
Primary completion :
08/01/2025
Completion :
02/01/2026
TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
|
cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (NCT05327894)
Phase 3
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric On...
Recruiting
Phase 3
Princess Maxima Center for Pediatric Oncology
Recruiting
Last update posted :
04/05/2024
Initiation :
12/15/2022
Primary completion :
09/01/2027
Completion :
09/01/2030
KMT2A
|
KMT2A rearrangement • MLL rearrangement
|
Blincyto (blinatumomab)
Venetoclax Basket Trial for High Risk Hematologic Malignancies (NCT05292664)
Phase 1
Andrew E. Place, MD
Andrew E. Place, MD
Recruiting
Phase 1
Andrew E. Place, MD
Recruiting
Last update posted :
04/02/2024
Initiation :
03/29/2023
Primary completion :
04/02/2025
Completion :
04/02/2027
FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1
|
KMT2A rearrangement • MLL rearrangement • IKZF1 deletion • ABL1 fusion • ABL1 deletion
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (NCT01684150)
Phase 1
Epizyme, Inc.
Epizyme, Inc.
Completed
Phase 1
Epizyme, Inc.
Completed
Last update posted :
03/26/2024
Initiation :
09/01/2012
Primary completion :
11/01/2015
Completion :
02/01/2016
KMT2A
|
MLL rearrangement
|
pinometostat (EPZ-5676)
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (AALL15P1) (NCT02828358)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/25/2024
Initiation :
04/01/2017
Primary completion :
09/30/2020
Completion :
09/22/2024
KMT2A
|
KMT2A rearrangement • MLL rearrangement
|
cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (NCT04307576)
Phase 3
Mats Heyman
Mats Heyman
Recruiting
Phase 3
Mats Heyman
Recruiting
Last update posted :
03/19/2024
Initiation :
07/13/2020
Primary completion :
06/30/2027
Completion :
06/30/2032
MYC • BCL2 • KMT2A
|
MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement
|
imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722)
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Cent...
Recruiting
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/13/2024
Initiation :
09/01/2010
Primary completion :
09/01/2025
Completion :
12/01/2025
FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
|
Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
|
cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies (NCT05011422)
Phase 1
Washington University School of Medicine
Washington University School of Medicine
Recruiting
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
03/11/2024
Initiation :
11/03/2022
Primary completion :
11/30/2027
Completion :
11/30/2027
FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10
|
MLL rearrangement • NUP98 rearrangement
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843)
Phase 2
City of Hope Medical Center
City of Hope Medical Center
Recruiting
Phase 2
City of Hope Medical Center
Recruiting
Last update posted :
03/06/2024
Initiation :
02/07/2020
Primary completion :
08/04/2025
Completion :
08/04/2025
FLT3 • CD8 • HLA-DRB1 • CD4 • NCAM1
|
MLL rearrangement
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation (NCT03434730)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
03/04/2024
Initiation :
02/07/2018
Primary completion :
02/07/2025
Completion :
02/07/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03494569)
Phase 1
City of Hope Medical Center
City of Hope Medical Center
Recruiting
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
02/22/2024
Initiation :
07/06/2018
Primary completion :
11/11/2028
Completion :
11/11/2028
FLT3 • NPM1 • HLA-DRB1 • HLA-B • HLA-C
|
MLL rearrangement
|
melphalan • fludarabine IV
A Study of BN104 in the Treatment of Acute Leukemia (NCT06052813)
Phase 1/2
BioNova Pharmaceuticals (Shanghai) LTD.
BioNova Pharmaceuticals (Shanghai) LTD.
Recruiting
Phase 1/2
BioNova Pharmaceuticals (Shanghai) LTD.
Recruiting
Last update posted :
02/21/2024
Initiation :
09/16/2023
Primary completion :
06/01/2026
Completion :
06/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) (NCT05507827)
Phase 1
Dr. Melody Smith, MD, MS
Dr. Melody Smith, MD, MS
Recruiting
Phase 1
Dr. Melody Smith, MD, MS
Recruiting
Last update posted :
02/20/2024
Initiation :
08/18/2022
Primary completion :
01/01/2037
Completion :
01/01/2037
CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C
|
KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
|
Orca-T • firicabtagene autoleucel (CRG-022)
Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/16/2024
Initiation :
04/08/2022
Primary completion :
06/01/2024
Completion :
06/01/2024
TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004)
Phase 1
City of Hope Medical Center
City of Hope Medical Center
Recruiting
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
01/30/2024
Initiation :
07/19/2022
Primary completion :
12/13/2024
Completion :
12/13/2024
FLT3 • NPM1 • IL2RA • ISG20
|
MLL rearrangement • IL2RA expression • Chr t(9;11)
|
melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (NCT03613532)
Phase 1
Jacqueline Garcia, MD
Jacqueline Garcia, MD
Recruiting
Phase 1
Jacqueline Garcia, MD
Recruiting
Last update posted :
01/26/2024
Initiation :
10/24/2018
Primary completion :
02/01/2025
Completion :
02/01/2026
KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2
|
TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type
|
Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (NCT00357565)
Phase 2
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Recruiting
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
01/26/2024
Initiation :
11/01/2005
Primary completion :
12/01/2025
Completion :
12/01/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia (V2-MA-1801) (NCT03826992)
Phase 1
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cin...
Recruiting
Phase 1
Children's Hospital Medical Center, Cincinnati
Recruiting
Last update posted :
01/25/2024
Initiation :
12/27/2018
Primary completion :
01/01/2025
Completion :
01/01/2026
KMT2A
|
MLL rearrangement
|
Venclexta (venetoclax) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy (NCT05009719)
Phase 1/2
St. Petersburg State Pavlov Medical University
St. Petersburg State Pavlov Medical Uni...
Active, not recruiting
Phase 1/2
St. Petersburg State Pavlov Medical University
Active, not recruiting
Last update posted :
01/04/2024
Initiation :
04/01/2021
Primary completion :
04/01/2023
Completion :
04/01/2024
TP53 • FLT3 • KMT2A • NUP98
|
TP53 mutation • MLL rearrangement
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT02446964)
Phase 1
City of Hope Medical Center
City of Hope Medical Center
Active, not recruiting
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/03/2024
Initiation :
06/25/2015
Primary completion :
06/15/2024
Completion :
06/15/2024
FLT3 • HLA-DRB1
|
MLL rearrangement • Chr t(9;11)
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Orphan Indications for CD19 Redirected Autologous T Cells (NCT04276870)
Phase 2
Stephan Grupp MD PhD
Stephan Grupp MD PhD
Recruiting
Phase 2
Stephan Grupp MD PhD
Recruiting
Last update posted :
12/19/2023
Initiation :
03/12/2020
Primary completion :
03/10/2028
Completion :
03/10/2037
CD19 • KMT2A
|
MLL rearrangement • CD19 expression
|
Kymriah (tisagenlecleucel-T)
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells (NCT01092026)
Phase N/A
Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel
Completed
Phase N/A
Universitair Ziekenhuis Brussel
Completed
Last update posted :
12/06/2023
Initiation :
11/01/2010
Primary completion :
09/01/2018
Completion :
09/01/2018
FLT3 • KMT2A
|
MLL rearrangement • MLL rearrangement
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login